Nyxoah SA (EBR:NYXH)
0.7900
-0.0390 (-4.70%)
At close: Oct 30, 2026
Nyxoah Revenue
Nyxoah had revenue of 7.68M EUR in the quarter ending June 30, 2026, with 472.76% growth. This brings the company's total for the last twelve months to 21.66M, up 339.14% year-over-year. In the year 2025, Nyxoah had annual revenue of 10.02M with 121.63% growth. That makes Nyxoah the 32,649th largest company in the world by revenue and 86th in Belgium.
Revenue (ttm)
21.66M
Revenue Growth
+339.14%
P/S Ratio
3.65
Revenue / Employee
140.67K
Employees
154
Market Cap
79.06M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 10.02M | 5.50M | 121.63% |
| Dec 31, 2024 | 4.52M | 173.00K | 3.98% |
| Dec 31, 2023 | 4.35M | 1.26M | 40.99% |
| Dec 31, 2022 | 3.08M | 2.23M | 261.97% |
| Dec 31, 2021 | 852.00K | 783.00K | 1,134.78% |
| Dec 31, 2020 | 69.00K | - | - |
| Dec 31, 2019 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| UCB SA | 8.52B |
| argenx SE | 5.21B |
| Fagron NV | 1.03B |
| Ion Beam Applications | 639.00M |
| European Medical Solutions | 51.36M |
| Hyloris Pharmaceuticals | 9.83M |
| Onward Medical | 8.42M |
| Sequana Medical NV | 105.50K |
Nyxoah News
- 3 days ago - Nyxoah price target lowered to $3 from $6 at Cantor Fitzgerald - TheFly
- 4 days ago - Nyxoah to Release Third Quarter 2026 Financial Results on November 5, 2026 - GlobeNewsWire
- 11 days ago - Nyxoah reports preliminary Q3 revenue EUR 9.2M, consensus EUR 9.93M - TheFly
- 11 days ago - Nyxoah cuts FY26 revenue view to EUR 33M-EUR 35M from EUR 36M-EUR 40M - TheFly
- 11 days ago - Nyxoah Announces Preliminary Results for the Third Quarter of 2026 and Adjusts Revenue Guidance for 2026 - GlobeNewsWire
- 15 days ago - Nyxoah presents complete ACCCESS U.S. study data, submits PMA supplement to FDA - TheFly
- 4 weeks ago - Nyxoah names Liam Kelly as CEO, succeeding Olivier Taelman - TheFly
- 4 weeks ago - Nyxoah Appoints Liam Kelly as Chief Executive Officer - GlobeNewsWire